<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shounak Das, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory drugs (NSAIDs), including <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, cause considerable morbidity and mortality related to gastric and duodenal mucosal injury [<a href="#rid1">1</a>]. Thus, prevention of NSAID-induced GI toxicity is an important clinical issue.</p><p>The prostaglandin E analog <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, H2 receptor antagonists, and proton pump inhibitors (PPIs) have been evaluated as prophylactic therapies for patients taking NSAIDs. In addition, the selective COX-2 inhibitors (coxibs) is another strategy for the reduction of NSAID-related gastroduodenal toxicity. However, concerns about cardiovascular toxicity has limited development and marketing of coxibs. (See  <a class="medical medical_review" href="/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs"</a> and  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p>Strategies for the primary prevention of gastroduodenal toxicity due to NSAIDs and low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> will be reviewed here. Emphasis will be placed upon studies that used clinically relevant end points (symptomatic ulcers and complicated ulcers, including bleeding, perforating, and obstructing ulcers). Studies using endoscopic detection of ulcers as the end point will be cited only when data on more meaningful clinical end points are sparse or lacking. The pathogenesis, treatment, and secondary prevention of NSAID-induced gastroduodenal injury are discussed separately. (See  <a class="medical medical_review" href="/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a> and  <a class="medical medical_review" href="/d/html/14.html" rel="external">"NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Studies have evaluated risk factors for gastroduodenal toxicity from nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and assessment of these factors is recommended for identifying patients who should be considered for primary prophylaxis if it is felt that an NSAID or low-dose aspirin must be given [<a href="#rid2">2-5</a>]. (See  <a class="medical medical_review" href="/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a>.)</p><p>One prospective study of 34,701 osteoarthritis and rheumatoid arthritis patients ages 50 and above randomized to either a coxib or <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> use found the following factors to be significant predictors for gastrointestinal (GI) toxicity including bleeding, perforation, obstruction, or uncomplicated ulcer: age &gt;64, a history of prior adverse GI events, or concurrent use of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid6">6</a>].</p><p>In the ASPREE primary prevention of cardiovascular disease trial of 19,114 persons aged 70 years or above, low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy increased upper GI bleeding (hazard ratio [HR] 1.87; 95% CI 1.32-2.66), without leading to significant cardiovascular benefit [<a href="#rid5">5</a>]. </p><p>According to 2008 American College of Cardiology Foundation/American College of Gastroenterology (ACG)/American Heart Association guidelines, patients with the following factors are considered to be at high risk for GI toxicity from NSAIDs [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>History of ulcer disease or ulcer complication</p><p class="bulletIndent1"><span class="glyph">●</span>On dual antiplatelet therapy</p><p class="bulletIndent1"><span class="glyph">●</span>On anticoagulant therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Have two or three of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥60 years</p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoid use</p><p class="bulletIndent2"><span class="glyph">•</span>Dyspepsia or gastroesophageal reflux disease symptoms</p><p></p><p>In separate guidelines from the ACG in 2009, patients taking NSAIDs were classified as being at high, moderate, or low risk for gastroduodenal toxicity [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>High risk was defined as a history of a complicated ulcer or ≥3 risk factors</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate risk was defined as the presence of one or two risk factors</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk was defined as none of the four risk factors</p><p></p><p>The four risk factors are:</p><p class="bulletIndent1"><span class="glyph">●</span>History of an uncomplicated ulcer</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;65 years</p><p class="bulletIndent1"><span class="glyph">●</span>High-dose NSAID therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (including low dose), glucocorticoids, or anticoagulants</p><p></p><p>Use of selective serotonin reuptake inhibitors (SSRIs) has also been associated with an increased risk of GI bleeding [<a href="#rid8">8,9</a>]. A meta-analysis of observational studies showed an odds ratio of 2.36 (1.44-3.85) for SSRI associated upper GI hemorrhage. The odds ratio increased to 6.33 (3.40-11.8) for concurrent SSRI and NSAID use [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a>.)</p><p>A large case series analysis involving over 100,000 patients with upper GI bleeding demonstrated that monotherapy with SSRIs, glucocorticoids, aldosterone antagonists, nitrates, and calcium channel blockers was associated with an increased risk of bleeding [<a href="#rid9">9</a>]. Furthermore, glucocorticoids and aldosterone antagonists added to the risk of bleeding when used together with nonselective NSAIDs [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2134667089"><span class="h1">NONSELECTIVE NSAIDs</span><span class="headingEndMark"> — </span>In a 2013 meta-analysis that utilized data from over 300,000 participants in over 750 trials, all NSAID regimens examined increased upper gastrointestinal complications including upper gastrointestinal perforation, obstruction, or bleeding (adjusted rate ratio [ARR] for <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> 1.89, 95% CI 1.2-3.1; <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 3.97, 95% CI 2.2-7.1; and <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> 4.2, 95% CI 2.7-6.6) when compared to placebo [<a href="#rid10">10</a>].</p><p>In another meta-analysis of controlled trials involving some of the most commonly prescribed NSAIDs, the following conclusions were reached [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of gastrointestinal complications was highest with <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> (relative risk [RR] 2.25), followed by <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> (RR 1.83), <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> (RR 1.73), <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a> (RR 1.66), <a class="drug drug_general" data-topicid="110865" href="/d/drug information/110865.html" rel="external">tenoxicam</a> (RR 1.43), <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> (RR 1.19), and <a class="drug drug_general" data-topicid="10295" href="/d/drug information/10295.html" rel="external">meloxicam</a> (RR 1.24).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk was related to the duration of treatment. The average duration of treatment before observing a significant risk of GI effects was 84 days. However, an increased risk was apparent as early as seven days with <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>.</p><p></p><p>Similar conclusions were reached in an earlier meta-analysis, which ranked the risk of various NSAIDs relative to <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>, which at the time was considered to have the lowest risk [<a href="#rid12">12</a>]. A ranking of increasing risk was found in the following order: ibuprofen, <a class="drug drug_general" data-topicid="8440" href="/d/drug information/8440.html" rel="external">fenoprofen</a>, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a>, <a class="drug drug_general" data-topicid="9967" href="/d/drug information/9967.html" rel="external">sulindac</a>, <a class="drug drug_general" data-topicid="9357" href="/d/drug information/9357.html" rel="external">diflunisal</a>, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a>, <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a>, and azapropazone.</p><p>A cohort study conducted in United States veterans suggests that the NSAID <a class="drug drug_general" data-topicid="8427" href="/d/drug information/8427.html" rel="external">etodolac</a> caused significantly fewer clinically significant upper gastrointestinal events than <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, an effect that was eliminated by concurrent treatment with low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid13">13</a>].</p><p>Ulcer risk also increased with higher doses of the NSAIDs in the aforementioned meta-analysis [<a href="#rid11">11</a>]. The following relative risks were observed in a subset of studies that had described GI toxicity relative to the dose of the NSAID:</p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> (RR 1.6, 95% CI 0.8-3.2)</p><p class="bulletIndent1"><span class="glyph">●</span>High-dose <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> (RR 4.2, 95% CI 1.8-9.8)</p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> (RR 3.7, 95% CI 1.7-7.7)</p><p class="bulletIndent1"><span class="glyph">●</span>High-dose <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> (RR 6.0, 95% CI 3.0-12.2)</p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> (RR 3.0, 95% CI 2.2-4.2)</p><p class="bulletIndent1"><span class="glyph">●</span>High-dose <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> (RR 7.0, 95% CI 4.4-11.2)</p><p></p><p>While the dosing cutoffs defining "high" versus "low" were somewhat arbitrary and varied across studies, they nevertheless support the observation that the risk associated with NSAIDs is related not only to the duration of therapy but also to the dose of treatment. (See  <a class="medical medical_review" href="/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Bleeding'</a>.) </p><p><a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">Ketorolac</a>, which was not included in the above meta-analyses, is also associated with a high risk of GI toxicity, particularly when used in higher doses, in older patients, and for more than five days [<a href="#rid14">14</a>]. One study found that ketorolac was 5.5 times more likely to cause GI toxicity than other NSAIDs [<a href="#rid15">15</a>]. Because of the risks associated with ketorolac (both gastrointestinal and renal), its use should be restricted to short-term pain treatment [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p class="headingAnchor" id="H2603523184"><span class="h1">ENTERIC-COATED AND BUFFERED ASPIRIN</span><span class="headingEndMark"> — </span>It has been proposed that a way to reduce gastrointestinal (GI) toxicity from <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> is the use of enteric-coated or buffered aspirin. Enteric-coated aspirin is designed to resist disintegration in the stomach, dissolving in the more neutral-to-alkaline environment of the duodenum. Although enteric-coated aspirin diminishes endoscopic signs of gastroduodenal injury, it does not protect against the clinically relevant end point of gastrointestinal bleeding [<a href="#rid18">18-22</a>]. In a placebo-controlled Australian/United States study in healthy older adults, enteric-coated aspirin 100 mg per day increased the risk of upper GI bleeding (HR 1.87; 95% CI, 1.32-2.66) without significantly reducing cardiovascular events [<a href="#rid22">22</a>]. These findings are not surprising, since injury severe enough to induce bleeding is thought to reflect the systemic rather than the topical effects of aspirin [<a href="#rid23">23</a>]. The systemic effect of aspirin on the stomach and duodenum also probably explains why buffered aspirin is no more effective than plain aspirin in preventing ulcer bleeding [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H1948110800"><span class="h2">Low-dose aspirin for cardiovascular protection</span><span class="headingEndMark"> — </span>Issues related to bleeding risk of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for primary cardiovascular protection are also discussed separately. (See  <a class="medical medical_review" href="/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H2963678719"><span class="h2">Dual antiplatelet therapy (eg, aspirin and clopidogrel)</span><span class="headingEndMark"> — </span>Issues related to GI bleeding with dual antiplatelet therapy in patients with cardiovascular disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H3541993414"><span class="h1">ROLE OF HELICOBACTER PYLORI</span><span class="headingEndMark"> — </span>Multiple studies have evaluated the relationship between <em>Helicobacter pylori</em> and the risk of peptic ulcer disease (PUD) in nonsteroidal anti-inflammatory drug (NSAID) users. (See  <a class="medical medical_review" href="/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a>.)</p><p>Based upon the available evidence, the following is a reasonable approach:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a history of uncomplicated or complicated peptic ulcers (gastric, duodenal) should be tested for <em>H. pylori</em> prior to beginning a course of NSAID or low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy. If present, <em>H. pylori </em>should be treated with appropriate therapy, even if it is believed that the prior ulcer was due to NSAIDs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In asymptomatic patients with no history of ulcer and not currently taking an NSAID, physicians can consider <em>H. pylori</em> testing prior to beginning long-term therapy with a NSAID. A review of this topic suggested that eradication of <em>H. pylori</em> was beneficial in patients who were naïve to NSAIDs, while little benefit was observed in patients already taking and tolerating NSAIDs [<a href="#rid24">24</a>]. This "test-and-treat" approach may be more useful in populations with a relatively high prevalence of <em>H. pylori</em> infection.</p><p></p><p class="headingAnchor" id="H8"><span class="h1">SELECTIVE COX-2 INHIBITORS (COXIBS)</span><span class="headingEndMark"> — </span>The primary effect of nonsteroidal anti-inflammatory drugs (NSAIDs) is to inhibit cyclooxygenase (COX), thereby impairing the transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. Two isoforms of COX exist: COX-1 and COX-2. COX-1 is constitutive and involved in gastric and duodenal cytoprotection [<a href="#rid25">25</a>], while COX-2 is inducible and involved in inflammation and perhaps healing of gastroduodenal lesions. It has been proposed that the ideal NSAID would inhibit the inducible COX-2 isoform (thereby decreasing tissue inflammation) without having any effect on the COX-l isoform (thereby minimizing gastrointestinal [GI] toxicity) [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action"</a> and  <a class="medical medical_review" href="/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs"</a>.)</p><p>Clinical trials and meta-analyses have evaluated the gastroduodenal toxicity of coxibs when compared to nonselective NSAIDs [<a href="#rid10">10</a>]. Detailed information regarding these trials is presented elsewhere. These data suggest that coxibs are associated with a reduced risk of gastrointestinal bleeding compared with nonselective NSAIDs but that the risk is increased compared with placebo. Thus, coxibs may be safer than conventional NSAIDs for reduction in the risk of gastrointestinal bleeding but are still associated with an increased risk. (See  <a class="medical medical_review" href="/d/html/10.html" rel="external">"COX-2 inhibitors and gastroduodenal toxicity: Major clinical trials"</a>.)</p><p>Any potential gastroduodenal sparing effect with coxibs may be abrogated when they are used concurrently with low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy for prevention of cardiovascular disease [<a href="#rid27">27</a>]. One population-based case control study found that coxibs were associated with a modest reduction in the risk of gastrointestinal bleeding compared with nonselective NSAIDs (RR 0.6, 95% CI 0.4-0.9 among aspirin nonusers) [<a href="#rid28">28</a>]. Concomitant use of aspirin negated the benefit of coxibs.</p><p>A case-control study suggested that patients taking <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> concomitantly with a nonselective NSAID or a coxib have an increased risk of hospitalization for upper gastrointestinal bleeding [<a href="#rid29">29</a>]. The magnitude of risk was similar, suggesting that the coxibs may not be GI-protective in this population.</p><p>Coxib usage declined with concerns related to their cardiovascular toxicity. In the Prospective Randomized Evaluation of <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">Celecoxib</a> Integrated Safety (PRECISION) trial in patients with arthritis pain, however, celecoxib was found to be non-inferior to <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> and <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> with respect to a composite primary cardiovascular endpoint [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">PREVENTION STRATEGIES</span><span class="headingEndMark"> — </span>Options for reducing the risk of gastroduodenal toxicity include (a) using a nonselective nonsteroidal anti-inflammatory drug (NSAID) together with a proton pump inhibitor (PPI) or <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> or (b) using a coxib with or without a PPI. The use of high-dose H2 blockers is reserved for patients who cannot tolerate PPIs or misoprostol.</p><p>Multiple studies have evaluated a variety of strategies for preventing ulcers in patients requiring NSAIDs. A meta-analysis of 112 randomized controlled trials found no evidence supporting the effectiveness of H2 receptor antagonists at standard doses [<a href="#rid31">31</a>]. However, the risk of symptomatic ulcers was significantly reduced by PPIs (relative risk [RR] 0.09, 95% CI 0.02-0.47) and by <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> (RR 0.36, 95% CI 0.02-0.65). Coxibs in place of a nonselective NSAID also reduced risk (RR 0.49, 95% CI 0.38-0.65). </p><p class="headingAnchor" id="H855394638"><span class="h2">Proton pump inhibitors</span><span class="headingEndMark"> — </span>PPIs are useful for the prevention of NSAID-induced and low-dose aspirin-induced ulcers [<a href="#rid32">32-38</a>]. The Prospective Randomized Evaluation of <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">Celecoxib</a> Integrated Safety (PRECISION) trial randomized OA or RA patients whose arthritis pain was resistant to <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and who were at increased risk for cardiovascular disease (nearly one-half taking low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>), but who were not at very high risk for ulcer disease (recent ulcer disease was an exclusionary criteria), to receive celecoxib (100 mg bid), <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> (600 mg tid), or <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> (375 mg bid) as initial NSAID doses to control arthritis pain plus <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a> (20 or 40 mg per day in each group). Clinically significant gastrointestinal (GI) events during a median follow up period of 34 months occurred in only 0.7 percent, 0.9 percent, and 0.7 percent of patients, respectively [<a href="#rid39">39</a>]. PPIs are better tolerated than <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1749992862"><span class="h2">Misoprostol</span><span class="headingEndMark"> — </span>The risk for NSAID-induced gastric or duodenal ulcer can be decreased with concomitant use of the prostaglandin E analog <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> [<a href="#rid39">39</a>]. In the largest trial, 8843 patients with rheumatoid arthritis receiving continuous therapy with any of 10 nonselective NSAIDs were randomly assigned to receive 200 mcg of misoprostol or placebo four times daily for six months [<a href="#rid2">2</a>]. Serious upper GI complications (bleeding, perforation, gastric outlet obstruction) were reduced in patients receiving misoprostol from 0.95 to 0.38 percent, a relative risk reduction of 40 percent, with an absolute risk reduction of 0.57 percent (ie, 175 patients needed to be treated to reduce one complication). However, more patients receiving misoprostol rather than placebo withdrew from the study during the first month (20 versus 15 percent), primarily because of diarrhea and abdominal discomfort. Misoprostol is not tolerated as well as PPIs [<a href="#rid31">31,33</a>].</p><p>Doses of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> lower than 200 mcg four times daily have fewer side effects [<a href="#rid39">39</a>]. These lower doses have not received FDA approval, and have not been shown to reduce clinically meaningful ulcer endpoints, however.</p><p class="headingAnchor" id="H2353985129"><span class="h3">PPI (lansoprazole) versus misoprostol</span></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacies of <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a> and <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> were compared in a multicenter trial in which 537 patients who were long-term NSAID users were randomly assigned to placebo, misoprostol (200 mcg four times daily), or one of two doses of lansoprazole (15 or 30 mg daily) [<a href="#rid33">33</a>]. After 12 weeks, the 49 percent incidence of endoscopically detected gastroduodenal ulceration with placebo and was significantly reduced with misoprostol (7 percent) and, to a lesser extent, with both doses of lansoprazole (20 and 18 percent, respectively). However, patient withdrawals were more common in the misoprostol group. </p><p></p><p class="headingAnchor" id="H2229417176"><span class="h3">PPI (esomeprazole) used with either nonselective NSAIDs or coxibs</span></p><p><a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">Esomeprazole</a> was evaluated for prevention of NSAID-associated ulcers based upon the results of two multicenter trials involving a total of 1429 patients who were taking NSAIDs continuously (nonselective or COX-2 selective, with or without low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>).</p><p>Patients were at increased risk for peptic ulcer disease (PUD) either because they were older than 60 or had a history of an ulcer. They were randomly assigned to co-therapy with a PPI (20 or 40 mg of <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a>) or placebo for six months. All patients were <em>H. pylori</em> negative and were free of active ulcer disease at randomization. The primary end point was endoscopically-detected ulcer development [<a href="#rid40">40</a>]. The major findings in both studies were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopic ulcers developed in a similar proportion of patients taking a nonselective NSAID or coxib without <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a> (17.1 versus 16.5 percent). This observation underscores that selective COX-2 inhibitors may not protect against endoscopic ulcer formation in these high-risk patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cumulative proportion of patients developing endoscopic ulcers at six months was significantly reduced with <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a> co-therapy (17 percent with placebo versus 5.2 and 4.6 percent with the 20 and 40 mg dose of esomeprazole, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The proportion of patients developing endoscopic ulcers who were taking a coxib plus <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a> was not significantly different from the proportion taking a nonselective NSAID plus esomeprazole (3 versus 6 percent). </p><p></p><p>Several important study limitations should be considered. First, only 17 percent of patients had a history of PUD and none had active ulcer disease at randomization and thus the studies focused mainly on primary prophylaxis in elderly patients. Second, patients were not randomized to a nonselective NSAID versus a selective coxib. Thus, patients who were considered to be at higher risk for UD may have been treated with a coxib, possibly accounting for the high rate of endoscopic ulcer in this group. Third, the studies analyzed patients receiving low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> as having received a nonselective NSAID even if they were taking a coxib. Fourth, the studies focused on endoscopic, not clinical, ulcer disease. </p><p class="headingAnchor" id="H502553862"><span class="h3">Coxib (celecoxib) versus naproxen plus lansoprazole, together with low-dose aspirin</span></p><p>A randomized endoscopic trial in low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> users compared <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> 200 mg per day with the combination of <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> 500 mg twice daily and <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a> [<a href="#rid41">41</a>]. There was no difference between these two approaches, with gastroduodenal ulcers seen in 10 and 9 percent of patients, respectively.</p><p class="headingAnchor" id="H1474645841"><span class="h3">Coxib (etoricoxib) versus diclofenac</span></p><p>Another randomized controlled trial assessed the cardiovascular toxicity of etoricoxib versus the nonselective NSAID <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> [<a href="#rid42">42</a>]. In a pre-specified analysis of GI toxicity, etoricoxib was associated with significantly less gastrointestinal toxicity regardless of PPI or ASA co-administration. This benefit held true only for uncomplicated GI events; there was no difference between the two groups for complicated GI events [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1503860687"><span class="h3">Nonselective NSAID with either a PPI or misoprostol versus a coxib</span></p><p>Data are conflicting about whether coxibs provide additional protection compared with conventional, nonselective NSAIDs that are combined with either a proton pump inhibitor or <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of 4484 patients with osteoarthritis or rheumatoid arthritis, 2238 patients were assigned to receive <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> and 2246 patients were assigned to receive <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> plus <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> [<a href="#rid43">43</a>]. Patients in the celecoxib arm were significantly less likely to develop GI toxicity compared with patients in the diclofenac/omeprazole arm (1 versus 4 percent, hazard ratio 4.3).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population based study compared 1382 patients with upper gastrointestinal complications who were taking a conventional NSAID or a coxib with 22,957 age- and sex-matched controls [<a href="#rid44">44</a>]. Co-therapy with a PPI or <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> or use of a coxib all significantly reduced the risk of upper gastrointestinal complications. COX-2 inhibitor use was not more likely to lower complications compared with PPIs but were superior to low-dose misoprostol. The combination of a coxib with a PPI was associated with a greater reduction in risk (adjusted OR 0.36 (95% CI 0.28-0.47) as compared to an OR of 0.67 (95% CI 0.48-0.95) for a PPI plus a conventional, nonselective NSAID.</p><p></p><p>The issue of using a coxib plus a PPI compared to a nonselective NSAID plus a PPI in patients at increased risk for PUD remains unsettled. The former approach is probably non-inferior but may not be superior [<a href="#rid30">30</a>]. Furthermore, the PPI <a class="drug drug_general" data-topicid="9519" href="/d/drug information/9519.html" rel="external">rabeprazole</a> was associated with more celecoxib-related small intestinal mucosal injury (mostly erosions as opposed to ulcers) than placebo plus <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> [<a href="#rid45">45</a>], although the clinical significance of this observation is unknown. </p><p class="headingAnchor" id="H18"><span class="h2">H2 receptor antagonists</span><span class="headingEndMark"> — </span>Standard doses of H2 receptor antagonists were not effective for the prevention of NSAID-induced gastric ulcers in most reports, although they may prevent duodenal ulcers [<a href="#rid46">46</a>]. Studies that detected a benefit on gastric ulcer prevention were short-term (12 to 24 weeks) and focused on endoscopic rather than clinical endpoints [<a href="#rid47">47,48</a>].</p><p>High-dose H2 receptor antagonists have also been studied. Again, the trials were short-term and focused on endoscopic endpoints. In two randomized trials (REDUCE-1 and REDUCE-2), patients who required daily NSAIDs for at least six months were assigned to receive either <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 800 mg plus <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> 26.6 mg or ibuprofen 800 mg three times per day [<a href="#rid49">49</a>]. The outcome of interest was ulcer development over 24 weeks of treatment. The pooled analysis of the two studies comparing the drug combination with ibuprofen alone found that the combination significantly reduced overall upper gastrointestinal ulcer development (14 versus 24 percent), gastric ulcer development (13 versus 21 percent), and duodenal ulcer development (2 versus 7 percent).</p><p class="headingAnchor" id="H18842643"><span class="h2">Aspirin-phosphatidylcholine combination</span><span class="headingEndMark"> — </span>A study in healthy volunteers between the ages of 50 and 74 found that combining 325 mg <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> per day with phosphatidylcholine reduced a combined endoscopic endpoint (petechiae, erosions, ulcers) compared with aspirin alone [<a href="#rid50">50</a>]. </p><p class="headingAnchor" id="H730276333"><span class="h2">Potassium-competitive acid blocker</span><span class="headingEndMark"> — </span>A novel agent, vonoprazan, has been shown to be non-inferior to the PPI <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a> in a double-blinded, randomized controlled study for the secondary prevention of NSAID-associated peptic ulcers [<a href="#rid51">51</a>]. Vonoprazan has been approved for use in Japan but is not available worldwide.</p><p class="headingAnchor" id="H9853419"><span class="h1">MONITORING PATIENTS TAKING NSAIDS</span><span class="headingEndMark"> — </span>Monitoring patients while on NSAIDs can be difficult since many patients who develop GI toxicity are asymptomatic until shortly before the adverse event occurs. An NSAID-induced gastrointestinal complication should be suspected if the patient develops unexplained blood loss anemia, iron deficiency, significant dyspepsia, or exhibits overt GI bleeding. The appropriate test to order is upper gastrointestinal endoscopy, unless ulcer perforation is suspected in which case computed tomography scan of the abdomen should be ordered immediately.</p><p class="headingAnchor" id="H826713291"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117750.html" rel="external">"Society guideline links: NSAID-related ulcer complications"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117855.html" rel="external">"Society guideline links: Peptic ulcer disease"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>As noted above, multiple studies have evaluated a variety of strategies for preventing ulcers in patients requiring prolonged nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for cardiovascular protection. The following represents recommendations based upon the available data and expert consensus.</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of gastroduodenal toxicity is related to risk factors described above, the patient's <em>Helicobacter pylori</em> (<em>H. pylori</em>) status, and the specific type and dose of NSAID. Significant gastrointestinal (GI) toxicity generally does not begin for several weeks, although it can appear as early as day 7 with some NSAIDs such as <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> or <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a>. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ability to modify the risk depends upon the clinical setting. As noted above, patients with a history of uncomplicated or complicated peptic ulcers (gastric, duodenal) should be tested for <em>H. pylori</em> prior to beginning long-term use of an NSAID or low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. If present, <em>H. pylori</em> should be treated with appropriate therapy, even if it is believed that the prior ulcer was due to NSAIDs. (See <a class="local">'Role of helicobacter pylori'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Attempts should be made to use the lowest dose and shortest duration of NSAID treatment that is feasible. While it is preferable to use NSAIDs with the lowest potential for GI toxicity, all NSAIDs are associated with an increased GI risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In asymptomatic patients with no history of ulcer and not currently taking an NSAID, physicians can consider <em>H. pylori</em> testing prior to beginning long-term therapy with a NSAID. It is possible that successfully treating <em>H. pylori</em> infection in such individuals will reduce the risk of NSAID-related ulcer complications, but additional studies of this approach are needed. This "test-and-treat" approach may be more useful in populations with a relatively high prevalence of <em>H. pylori</em> infection. In patients with a history of peptic ulcer disease or ulcer complications requiring an NSAID or low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, we recommend testing for <em>H. pylori</em> and treating for <em>H. pylori</em> if positive (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have multiple risk factors for NSAID-related gastroduodenal toxicity, options include therapy with a coxib or a nonselective NSAID in combination with a proton pump inhibitor (PPI) or <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>. High-dose H2 receptor antagonists are reserved for patients who cannot tolerate PPIs or misoprostol. (See <a class="local">'Risk factors'</a> above and <a class="local">'Selective COX-2 inhibitors (COXIBS)'</a> above and <a class="local">'Proton pump inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend co-administration of a PPI in patients who require an NSAID and are at high or moderate risk for GI toxicity (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Risk factors'</a> above.) We prefer PPIs to other preventive approaches because of their convenience and relatively good safety profile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approved doses of these ulcer prevention drugs in patients taking nonselective NSAIDs include <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> (200 mcg four times daily), <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a> (15 or 30 mg daily), and <a class="drug drug_general" data-topicid="9104" href="/d/drug information/9104.html" rel="external">esomeprazole</a> (20 or 40 mg daily). Although not all PPIs have received FDA approval, they probably all have similar effectiveness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a coxib is used, it is important to realize that any GI protective effect may be eliminated or reduced with the concomitant use of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for cardiovascular prophylaxis. (See <a class="local">'Coxib (celecoxib) versus naproxen plus lansoprazole, together with low-dose aspirin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An NSAID-induced gastrointestinal complication should be suspected if the patient develops unexplained blood loss anemia, iron deficiency, severe dyspepsia, or exhibits overt GI bleeding. Patients who develop NSAID-induced non-ulcer dyspepsia may respond to H2 receptor antagonists or PPIs at standard doses, but of these choices only PPIs also reliably reduce the risk of NSAID-induced ulcer or its complications. Development of dyspepsia may signal that an ulcer has developed at which point an upper endoscopy can be considered. Switching to a different NSAID or to a coxib may eliminate dyspepsia and obviate the need for an H2 antagonist or PPI. <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> does not reduce, and may even increase, dyspeptic symptoms. (See <a class="local">'Monitoring patients taking NSAIDs'</a> above and <a class="local">'Misoprostol'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112:1000.</a></li><li><a class="nounderline abstract_t">Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241.</a></li><li><a class="nounderline abstract_t">Simon LS, Hatoum HT, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996; 28:204.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52:1502.</a></li><li><a class="nounderline abstract_t">Mahady SE, Margolis KL, Chan A, et al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut 2021; 70:717.</a></li><li><a class="nounderline abstract_t">Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010; 32:1240.</a></li><li><a class="nounderline abstract_t">Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728.</a></li><li><a class="nounderline abstract_t">Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 27:31.</a></li><li><a class="nounderline abstract_t">Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147:784.</a></li><li><a class="nounderline abstract_t">Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382:769.</a></li><li><a class="nounderline abstract_t">Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004; 63:759.</a></li><li><a class="nounderline abstract_t">Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312:1563.</a></li><li><a class="nounderline abstract_t">Weideman RA, Kelly KC, Kazi S, et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology 2004; 127:1322.</a></li><li><a class="nounderline abstract_t">Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA 1996; 275:376.</a></li><li><a class="nounderline abstract_t">García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158:33.</a></li><li><a class="nounderline abstract_t">Reinhart DI. Minimising the adverse effects of ketorolac. Drug Saf 2000; 22:487.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019645s017lbl.pdf (Accessed on May 08, 2012).</li><li><a class="nounderline abstract_t">Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979; 91:517.</a></li><li><a class="nounderline abstract_t">Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993; 15:314.</a></li><li><a class="nounderline abstract_t">Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32:77.</a></li><li><a class="nounderline abstract_t">Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413.</a></li><li><a class="nounderline abstract_t">McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018; 379:1509.</a></li><li><a class="nounderline abstract_t">van Oijen MG, Dieleman JP, Laheij RJ, et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008; 6:309.</a></li><li><a class="nounderline abstract_t">Kiltz U, Zochling J, Schmidt WE, Braun J. Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? Rheumatology (Oxford) 2008; 47:1342.</a></li><li><a class="nounderline abstract_t">Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132:134.</a></li><li><a class="nounderline abstract_t">Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353:307.</a></li><li><a class="nounderline abstract_t">Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247.</a></li><li><a class="nounderline abstract_t">García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132:498.</a></li><li><a class="nounderline abstract_t">Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165:189.</a></li><li><a class="nounderline abstract_t">Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375:2519.</a></li><li><a class="nounderline abstract_t">Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329:948.</a></li><li><a class="nounderline abstract_t">Tamura A, Murakami K, Kadota J, OITA-GF Study Investigators. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM 2011; 104:133.</a></li><li><a class="nounderline abstract_t">Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162:169.</a></li><li><a class="nounderline abstract_t">Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.</a></li><li><a class="nounderline abstract_t">Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31:753.</a></li><li><a class="nounderline abstract_t">Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12:135.</a></li><li><a class="nounderline abstract_t">Lin KJ, Hernández-Díaz S, García Rodríguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011; 141:71.</a></li><li><a class="nounderline abstract_t">Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut 2020; 69:617.</a></li><li><a class="nounderline abstract_t">Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123:344.</a></li><li><a class="nounderline abstract_t">Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101:701.</a></li><li><a class="nounderline abstract_t">Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007; 5:1167.</a></li><li><a class="nounderline abstract_t">Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369:465.</a></li><li><a class="nounderline abstract_t">Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376:173.</a></li><li><a class="nounderline abstract_t">Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008; 134:937.</a></li><li><a class="nounderline abstract_t">Washio E, Esaki M, Maehata Y, et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol 2016; 14:809.</a></li><li><a class="nounderline abstract_t">Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996; 156:2321.</a></li><li><a class="nounderline abstract_t">Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334:1435.</a></li><li><a class="nounderline abstract_t">Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:119.</a></li><li><a class="nounderline abstract_t">Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012; 107:379.</a></li><li><a class="nounderline abstract_t">Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 2011; 106:272.</a></li><li><a class="nounderline abstract_t">Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018; 67:1042.</a></li></ol></div><div id="topicVersionRevision">Topic 35 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041264" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611589" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8900554" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017521" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32747412" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955443" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240698" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Guidelines for prevention of NSAID-related ulcer complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919277" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24937265" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk of upper gastrointestinal bleeding from different drug combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23726390" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194568" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664664" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521001" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569017" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9437376" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10877042" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Minimising the adverse effects of ketorolac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10877042" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Minimising the adverse effects of ketorolac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/314764" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8519040" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Endoscopic comparison of three aspirin preparations and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1888645" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937281" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30221597" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242146" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477642" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10644275" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9929039" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : COX-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979111" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17258728" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668365" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959716" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15475342" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870780" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11802750" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12087138" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8858742" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692687" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21458456" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31937550" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7625622" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16494585" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916545" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17292766" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20638563" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294634" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538205" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8911239" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618582" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19577798" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22186979" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081908" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988197" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
